...
首页> 外文期刊>Infection and immunity >A Replicating Adenovirus Capsid Display Recombinant Elicits Antibodies against Plasmodium falciparum Sporozoites in Aotus nancymaae Monkeys
【24h】

A Replicating Adenovirus Capsid Display Recombinant Elicits Antibodies against Plasmodium falciparum Sporozoites in Aotus nancymaae Monkeys

机译:一个复制的腺病毒衣壳展示重组抗体针对南猿猴中的恶性疟原虫子孢子的抗体。

获取原文
           

摘要

Decades of success with live adenovirus vaccines suggest that replication-competent recombinant adenoviruses (rAds) could serve as effective vectors for immunization against other pathogens. To explore the potential of a live rAd vaccine against malaria, we prepared a viable adenovirus 5 (Ad5) recombinant that displays a B-cell epitope from the circumsporozoite protein (CSP) of Plasmodium falciparum on the virion surface. The recombinant induced P. falciparum sporozoite-neutralizing antibodies in mice. Human adenoviruses do not replicate in mice. Therefore, to examine immunogenicity in a system in which, as in humans, the recombinant replicates, we constructed a similar recombinant in an adenovirus mutant that replicates in monkey cells and immunized four Aotus nancymaae monkeys. The recombinant replicated in the monkeys after intratracheal instillation, the first demonstration of replication of human adenoviruses in New World monkeys. Immunization elicited antibodies both to the Plasmodium epitope and the Ad5 vector. Antibodies from all four monkeys recognized CSP on intact parasites, and plasma from one monkey neutralized sporozoites in vitro and conferred partial protection against P. falciparum sporozoite infection after passive transfer to mice. Prior enteric inoculation of two animals with antigenically wild-type adenovirus primed a response to the subsequent intratracheal inoculation, suggesting a route to optimizing performance. A vaccine is not yet available against P. falciparum, which induces the deadliest form of malaria and kills approximately one million children each year. The live capsid display recombinant described here may constitute an early step in a critically needed novel approach to malaria immunization.
机译:活腺病毒疫苗的数十年成功经验表明,具有复制能力的重组腺病毒(rAds)可以用作针对其他病原体进行免疫接种的有效载体。为了探索针对疟疾的活rAd疫苗的潜力,我们制备了一种可行的腺病毒5(Ad5)重组体,该重组体在恶性疟原虫的环子孢子蛋白(CSP)上在病毒体表面显示B细胞表位。重组诱导的小鼠恶性疟原虫子孢子中和抗体。人腺病毒不会在小鼠中复制。因此,为了检查在其中与人类一样在其中复制的系统中的免疫原性,我们在腺病毒突变体中构建了在猴细胞中复制的相似重组体,并免疫了四只Aotus nancymaae猴。气管内滴注后,重组体在猴中复制,这是新世界猴中人腺病毒复制的首次证明。免疫引发了针对疟原虫表位和Ad5载体的抗体。来自所有四只猴子的抗体识别完整寄生虫上的CSP,并且一只猴子的血浆在体外中和了子孢子,并在被动转移给小鼠后对恶性疟原虫子孢子的感染提供了部分保护。两只动物的先前用抗原性野生型腺病毒进行肠内接种引发了对随后气管内接种的反应,这表明了优化性能的途径。目前还没有针对恶性疟原虫的疫苗,该疫苗可诱发最致命的疟疾形式,每年杀死约一百万儿童。本文所述的活衣壳展示重组体可能构成了急需的疟疾免疫新方法的第一步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号